# Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

> **NCT00721760** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 1003 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Enoxaparin sodium
- **DRUG:** Semuloparin sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00721760
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 1003 (ACTUAL)
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721760, "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00721760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*